Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-11-18
2009-06-02
Qazi, Sabiha N. (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reexamination Certificate
active
07541348
ABSTRACT:
Compounds of formula I are provided where X1and X2are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.
REFERENCES:
patent: 4666634 (1987-05-01), Miyamoto et al.
patent: 5086191 (1992-02-01), DeLuca et al.
patent: 5536713 (1996-07-01), DeLuca et al.
patent: 5585369 (1996-12-01), DeLuca et al.
patent: 5843928 (1998-12-01), DeLuca et al.
patent: 5891865 (1999-04-01), DeLuca et al.
patent: 5936105 (1999-08-01), Paaren
patent: 5945410 (1999-08-01), DeLuca et al.
patent: 6127559 (2000-10-01), DeLuca et al.
patent: 6392071 (2002-05-01), DeLuca et al.
patent: 6440953 (2002-08-01), DeLuca et al.
patent: 6537981 (2003-03-01), DeLuca et al.
patent: 6566352 (2003-05-01), DeLuca et al.
patent: 6579861 (2003-06-01), DeLuca et al.
patent: 6627622 (2003-09-01), DeLuca et al.
patent: 2004/0220418 (2004-11-01), DeLuca et al.
Baggiolini, et al., “Stereocontrolled Total Synthesis of 1α,25-Dihydroxycholecalciferol and 1α,25-Dihydroxyergocalciferol,” J. Org. Chem. 51, 3098 (1986).
Daniewski, et al., “A Novel Silylcopper Catalyst for the Reductive Bromination of Hajos Dione. Improved Preparation of a CD Synthon for the Synthesis of Vitamin D,” J. Org. Chem. 66, 626-628 (2001).
Mascareñas, et al., “Studies of the Synthesis of Side-Chain Hydroxylated Metabolites of Vitamin D. 3. Synthesis of 25-Ketovitamin D3and 25-Hydroxyvitamin D3,” J. Org. Chem. 51, 1269 (1986).
Posner, et al., “2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing,” J. Org. Chem. 60, 4617 (1995).
Lythgoe, et al., “Calciferol and its Relatives. Part 22. A Direct Total Synthesis of Vitamin D2and Vitamin D3,” J. Chem. Soc. Perkin Trans. I, N6, 590 (1978).
Lythgoe, “Synthetic Approaches to Vitamin D and its Relatives,” Chem. Soc. Rev. 9, 449 (1983).
Mincione, et al., “Improved Conversion of Vitamin D2into the Windaus Ketone and its Regioselective Hydroxylation via Organoboranes at C26,” Synth. Commun 19, 723 (1989).
Miyamoto, et al., “Synthetic Studies of Vitamin D Analogues. XIV. Synthesis and Calcium Regulating Activity of Vitamin D3Analogues Bearing a Hydroxyalkoxy Group at the 2β—Position,” Chem. Pharm. Bull. 41(6), 1111 (1993).
Nishii, et al., “The Development of Vitamin D3Analogues for the Treatment of Osteoporosis,” Osteoporosis Int. Suppl. 1, 190 (1993).
Okano, et al., “Regulatory Activities of 2β-(3-Hydroxypropoxy) -1α, 25-Dihydroxy-Vitamin D3, a Novel Synthetic Vitamin D3Derivative, on Calcium Metabolism,” Biochem. Biophys. Res. Commun. 163(3), 1444 (1989).
Ostrem, et al., “24- and 26-homo-1,25-dihydroxyvitamin D3: Preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro,” Proc. Natl. Acad. Sci. USA, 84, 2610 (1987).
Perlman, et al., “1α,25-Dihydroxy-19-Nor-Vitamin D3, a Novel Vitamin D-related Compound with Potential Therapeutic Activity,” Tetrahedron Lett. 31(13), 1823 (1990).
Perlman et al., “Novel Synthesis of 19-Nor-Vitamin D Compounds,” Tetrahedron Lett. 32(52), 7663 (1991).
Peterson, et al., “Studies of the Ketone Obtained from the Ozonolysis of Vitamin D. Molecular Mechanics Calculations for It and Related Hydrindanones,” J. Org. Chem. 51, 1948 (1986).
Posner, et al., “Stereocontrolled Total Synthesis of Calcitrol Derivatives: 1,25-Dihydroxy-2-(4'-hydroxybutyl)vitamin D3Analogs of an Osteoporosis Drug,” J. Org. Chem. 59, 7855 (1994).
Sardina, et al., “Studies on the Synthesis of Side-Chain Hydroxylated Metabolites of Vitamin D. 2. Stereocontrolled Synthesis of 25-Hydroxyvitamin D2,” J. Org. Chem. 51, 1264 (1986).
Sicinski, R.R., et al., “New 1α,25-Dihydroxy-19-norvitamin D3Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues,” J. Med. Chem., 41, 4662-4674 (1998).
Toh et al., “Studies on a Convergent Route to Side-Chain Analogues of Vitamin D: 25-Hydroxy-23-oxavitamin D3,” J. Org. Chem. 48, 1414 (1983).
International Search Report dated May 22, 2006 for PCT/US2005/041888.
International Search Report dated May 25, 2006 for PCT/US2005/041886.
International Search Report dated May 25, 2006 for PCT/US2005/041887.
Clagett-Dame Margaret
DeLuca Hector F.
Plum Lori A.
Foley & Lardner LLP
Qazi Sabiha N.
Wisconsin Alumni Research Foundation
LandOfFree
2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalc... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalc..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalc... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4118392